Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology. Dermira is focused on delivering important new therapies to the millions of patients living with chronic skin conditions, such as primary axillary hyperhidrosis. The company uses its experience and insight to identify and develop additional leading-edge medical dermatology pre-clinical programs.
Dermira recently acquired rights to Lebrikizumab, an IL-13 blocking antibody for the treatment of atopic dermatitis. We believe this acquisition is highly synergistic with Dermira’s existing product portfolio and will allow the company to leverage its infrastructure in the dermatology space.